Johnson & Johnson's Icotyde showed 58% ACR20 response in psoriatic arthritis, outperforming placebo in a 552-patient trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results